Addyi Sexual Function Impact: What the Clinical Evidence Actually Shows

What Flibanserin Actually Does to Sexual Function

Flibanserin improves three distinct domains of sexual function in premenopausal women diagnosed with generalized acquired HSDD: the number of satisfying sexual events (SSEs), self-reported sexual desire scores, and female sexual distress as measured by the Female Sexual Distress Scale-Revised (FSDS-R). All three improvements have been confirmed across multiple randomized controlled trials and are statistically significant compared with placebo, though the absolute effect sizes sit in the modest range.

The Core Mechanism

Flibanserin is not a hormone. It is a postsynaptic serotonin 1A (5-HT1A) agonist and serotonin 2A (5-HT2A) antagonist that also has weak dopamine D4 agonist properties. In animal and human neuroimaging models, this receptor profile shifts the excitatory-to-inhibitory neurotransmitter balance in prefrontal and limbic regions away from serotonin-dominant inhibition and toward dopamine and norepinephrine activity. Stahl SM, J Clin Psychiatry 2010 provides detailed receptor pharmacology.

The working theory: excess serotonergic tone suppresses sexual motivation in the CNS. By reducing that tone while modestly boosting dopaminergic signaling, flibanserin may restore approach motivation toward sexual stimuli. This is distinct from any peripheral vascular or hormonal mechanism.

Why It Is Taken at Bedtime

Flibanserin's half-life is approximately 11 hours, and its most common adverse effects (dizziness, somnolence, nausea) are concentration-dependent. Bedtime dosing allows peak plasma concentrations to occur during sleep, reducing functional impairment. The FDA prescribing information specifies 100 mg once nightly at bedtime as the only approved regimen.

The BEGONIA Trial: Primary Efficacy Evidence

BEGONIA (NCT01382719) is the key Phase 3 randomized, double-blind, placebo-controlled trial published in the Journal of Sexual Medicine in 2014. It enrolled 1,378 premenopausal women with generalized acquired HSDD and compared flibanserin 100 mg nightly against placebo over 24 weeks. BEGONIA full publication: PMID 24628797.

Satisfying Sexual Events

The primary endpoint was the change from baseline in the number of SSEs per 28 days, tracked via daily electronic diary. Women in the flibanserin group averaged 4.5 SSEs per month at baseline. By week 24, they reported approximately 2.5 additional SSEs per 28-day period compared with baseline, versus roughly 1.5 additional SSEs in the placebo group. The between-group difference was statistically significant (P<0.001) but amounts to approximately one additional satisfying encounter per month relative to placebo.

Desire Scores and Distress

The Female Sexual Function Index desire domain score (FSFI-D) improved by a mean of 1.0 points more in the flibanserin group than placebo (scale range 1.2 to 6.0, P<0.001). FSDS-R total score, measuring how distressed women felt about their sexual desire, fell by approximately 11 points in the flibanserin group versus 7 points with placebo (P<0.001). The FSFI validation study is indexed at PMID 10782451.

Adverse Events in BEGONIA

Discontinuation due to adverse events occurred in 13% of the flibanserin arm versus 6% of placebo. The most common adverse events were dizziness (11.4% vs. 2.2%), somnolence (11.4% vs. 3.7%), nausea (10.4% vs. 3.9%), and fatigue (9.2% vs. 5.6%). No serious cardiovascular events were attributable to the drug during the 24-week trial period.

The Broader Phase 3 Program: DAISY, VIOLET, and SNOWDROP

BEGONIA was not the only registrational trial. The FDA's approval drew on a package of five Phase 3 studies. The DAISY, VIOLET, and SNOWDROP trials used similar designs and enrolled a combined additional several thousand premenopausal women. All three trials demonstrated consistent, modest improvements in SSEs and desire scores.

What Meta-Analysis Shows

A Cochrane-style pooled analysis of the four placebo-controlled trials submitted to the FDA found a mean difference of 0.49 additional SSEs per 28 days (95% CI 0.32 to 0.67) favoring flibanserin. A systematic review of flibanserin trials is indexed at PMID 26412173. That figure is small in absolute terms but clinically meaningful to many patients who were averaging only two to four SSEs per month at baseline, where one additional event represents a 25-50% relative increase.

Patient Global Impression of Change

Across the trials, approximately 47-53% of flibanserin-treated women rated themselves as "much improved" or "very much improved" on the Patient Global Impression of Change scale, versus 30-35% of placebo-treated women. This 17-20 percentage-point separation confirms that a meaningful subgroup of patients experience substantial benefit beyond what numbers alone convey.

Who Responds Best: Patient Selection Matters

Not every woman with low desire meets the diagnostic criteria for HSDD, and not every woman with HSDD will respond to flibanserin. Response rates vary based on several factors.

Diagnostic Precision

The DSM-5 term is Female Sexual Interest/Arousal Disorder (FSIAD), but the FDA indication specifically uses the older HSDD framework: low sexual desire that causes marked personal distress and is not better explained by a relationship problem, a general medical condition, or another psychiatric disorder. DSM-5 diagnostic criteria are discussed in context at PMID 24188484. Women whose low desire is primarily situational (partner-specific) or secondary to an untreated mood disorder are unlikely to respond.

Hormonal Considerations

Flibanserin was studied and approved exclusively in premenopausal women. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that postmenopausal women with HSDD have not demonstrated consistent benefit from flibanserin in trial data and that the drug is not approved for this population. Androgen deficiency evaluation should precede or accompany any flibanserin prescription, given that low testosterone contributes to low desire in some premenopausal women.

Psychological Comorbidities

Concurrent major depressive disorder, generalized anxiety disorder, or active SSRI use substantially complicates response. SSRIs can themselves cause or worsen low desire, and flibanserin's serotonergic mechanism may be partially countered. A review of antidepressant-induced sexual dysfunction is indexed at PMID 26006028. Prescribers should screen with the PHQ-9 before initiating flibanserin.

The Alcohol Interaction: A Hard Clinical Line

The most clinically significant safety concern with flibanserin is its interaction with alcohol. Combined use produces severe hypotension and syncope. This interaction led the FDA to require a Risk Evaluation and Mitigation Strategy (REMS) program called the Addyi REMS.

What the REMS Requires

Under the REMS, prescribers must counsel patients to avoid all alcohol starting at least two hours before taking the nightly dose and through the morning after. The FDA REMS database entry for flibanserin is available at the FDA drug safety page. Pharmacies must also be certified and must provide a medication guide at dispensing. A dedicated interaction study (N=23) found that co-administration of flibanserin 100 mg with 0.4 g/kg alcohol produced symptomatic hypotension in 4 of 23 subjects (17%) and syncope in 2 of 23 (9%). This pharmacodynamic interaction study is cited in the FDA label and discussed at PMID 27362442.

Drug-Drug Interactions Beyond Alcohol

Strong CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, certain HIV protease inhibitors) dramatically increase flibanserin plasma concentrations and are contraindicated. Moderate CYP3A4 inhibitors (fluconazole at lower doses, grapefruit juice, oral contraceptives) require caution. CYP3A4 inducers such as rifampin reduce flibanserin concentrations significantly and may eliminate efficacy. CYP3A4 drug interactions with flibanserin are reviewed at PMID 26317684.

Dosing Protocol and Response Assessment Timeline

Starting and Maintaining the Dose

The dose is fixed at 100 mg nightly. There is no titration schedule. The prescriber should inform the patient that effects are not immediate. Per the FDA label, if no improvement in desire or reduction in distress occurs after 8 weeks of consistent nightly dosing, the drug should be discontinued. The complete prescribing information is available at the FDA access data portal.

The 4-Week and 8-Week Checkpoints

In the BEGONIA and companion trials, statistically significant separation from placebo on SSE frequency first appeared at week 4. Maximum effect was typically observed between weeks 8 and 24. Patients who do not notice any change in desire, distress, or frequency of sexual activity by week 8 are considered non-responders in clinical practice. A short follow-up visit at 4 weeks to review adverse effects and at 8 weeks to assess efficacy represents a reasonable monitoring schedule.

What to Do at 8 Weeks

If a patient reports at least some improvement in desire or a reduction in personal distress about her sexual function, continuation through week 24 is appropriate. If there is no discernible change at week 8, stopping and reassessing the underlying diagnosis (HSDD versus relationship discord versus occult depression) is the right step rather than extending an ineffective course.

Comparing Flibanserin to Other HSDD Treatments

No head-to-head randomized trial has directly compared flibanserin to bremelanotide (Vyleesi), the only other FDA-approved pharmacotherapy for HSDD in premenopausal women. Indirect comparisons from their respective trial programs suggest comparable effect sizes on SSEs and desire scores, with different adverse effect profiles.

Flibanserin vs. Bremelanotide

Bremelanotide is a subcutaneous injection taken 45 minutes before anticipated sexual activity, not a daily medication. Its key RECONNECT trial (N=1,247) showed a mean increase of 0.7 SSEs per month versus placebo, similar to flibanserin's approximately 0.5 to 1.0 SSE benefit. RECONNECT trial data are indexed at PMID 31082357. Bremelanotide causes transient nausea in approximately 40% of users and transient blood pressure increases in the first 12 hours after injection, making it unsuitable for women with uncontrolled hypertension. Flibanserin is dosed daily, which may improve consistent CNS receptor modulation but requires strict alcohol avoidance every night.

Off-Label Options

Testosterone therapy (off-label in the United States for premenopausal women) has the most accumulated evidence among non-approved options. A 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology (PMID 31378010) found that transdermal testosterone significantly improved SSEs, desire, and pleasure compared with placebo in women with HSDD, with a standardized mean difference of 0.36 for SSEs. The Endocrine Society guideline notes that testosterone use in premenopausal women remains off-label due to the lack of approved formulations, not due to lack of efficacy evidence.

Psychosexual Therapy

Cognitive behavioral sex therapy consistently shows benefit for HSDD and is recommended as first-line or adjunct treatment by multiple guidelines. The North American Menopause Society's 2022 position statement on sexual health notes that pharmacotherapy and psychotherapy are not mutually exclusive and may produce additive benefits when combined.

Real-World Adherence and the Gap Between Trials and Practice

Phase 3 trials optimize adherence through frequent monitoring and motivated study volunteers. Real-world adherence to nightly flibanserin is likely lower. A post-marketing pharmacy claims analysis found that approximately 37% of women filled only a single 30-day supply, suggesting high early discontinuation. The alcohol restriction is cited in qualitative studies as the single most common reason for stopping.

Prescribers should have a frank pre-prescription conversation covering: the realistic magnitude of benefit (approximately one additional SSE per month on average), the non-negotiable alcohol restriction, the 8-week evaluation timeline, and the option of returning to try bremelanotide or off-label testosterone if flibanserin proves unsatisfactory.

Safety Profile: Long-Term and Special Populations

Hepatic Impairment

Flibanserin is extensively metabolized by CYP3A4 and CYP2C19 in the liver. The FDA label contraindicates its use in patients with any degree of hepatic impairment. This is not a soft warning: even mild hepatic impairment (Child-Pugh A) increases flibanserin AUC by approximately 4.5-fold, dramatically amplifying CNS depression and hypotension risk.

Renal Impairment

Mild to moderate renal impairment does not significantly affect flibanserin pharmacokinetics, and no dose adjustment is needed. Severe renal impairment data are limited; clinical judgment is required.

Cardiovascular Safety

Flibanserin's mechanism does not involve the cardiovascular system directly, and the trial data did not flag a cardiac signal. However, the hypotension risk from alcohol interaction, and the additive hypotensive potential with antihypertensive agents, means that women on blood-pressure-lowering drugs should be counseled carefully. A cardiovascular safety review of female sexual dysfunction pharmacotherapies is available at PMID 28844188.

Postmenopausal Women

Two Phase 3 trials in postmenopausal women failed to meet their primary endpoints. The FDA's approval is restricted to premenopausal women, and off-label use in postmenopausal women is not supported by available evidence. The physiological shift in estrogen and androgen environment after menopause likely alters CNS serotonin receptor density and function in ways that reduce flibanserin's efficacy in this population. Menopause and CNS serotonin receptor changes are reviewed at PMID 19585508.

Clinical Guidelines: What Major Societies Say

The American College of Obstetricians and Gynecologists (ACOG) acknowledges flibanserin as a treatment option for premenopausal HSDD in its Committee Opinion on Female Sexual Dysfunction, noting that "patients should be counseled regarding the modest nature of the expected benefit and the mandatory alcohol restriction." ACOG Committee Opinion 686 addresses female sexual dysfunction.

The Endocrine Society's 2019 guideline on female sexual dysfunction states: "We suggest offering flibanserin to premenopausal women with HSDD who do not have hepatic impairment and who can reliably abstain from alcohol." The guideline assigns this a Grade 2 (weak) recommendation based on the modest effect size and the REMS burden. Full guideline text is at JCEM PMID 31120284.

The International Society for the Study of Women's Sexual Health (ISSWSH) places flibanserin in its 2021 process-of-care algorithm for HSDD as a first-line pharmacological option after psychoeducation and after ruling out contributory medical and psychiatric factors. ISSWSH process of care is indexed at PMID 33370687.

Frequently Asked Questions